Lipocine Inc.
LPCNNASDAQHealthcare● Active
$2.08
+$0.04(+1.72%)
Market Cap$12042277
P/E Ratio—
52W High$12.37
52W Low$1.81
Lipocine Inc. (LPCN) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
LPCN · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.54
Est. -$0.51 · -5.9%
Revenue
$0.00B
Est. $0.00B · +634.8%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
LPCN reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$-0.01
Rev. $0.48B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$-0.01
Rev. Est.$0.48B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 4, 2026 | -$0.47 | — | — | — | $0.00B | — |
| ▼ Q2 FY2026 | May 7, 2026 | -$0.51 | -$0.54 | -5.9% | $0.00B | $0.00B | +634.8% |
| ▲ Q1 FY2026 | Mar 9, 2026 | -$0.60 | -$0.34 | +43.3% | $0.00B | $0.00B | +867.8% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -$0.56 | -$0.59 | -5.4% | $0.00B | $0.00B | -51.9% |
| — Q3 FY2025 | Aug 5, 2025 | -$0.41 | -$0.41 | +0.0% | $0.00B | $0.00B | +161.7% |
| — Q2 FY2025 | May 8, 2025 | -$0.35 | -$0.35 | +0.0% | $0.00B | $0.00B | -73.3% |
| ▲ Q1 FY2025 | Mar 13, 2025 | -$0.40 | $0.33 | +182.5% | $0.00B | $0.00B | +33.6% |
| ▲ Q4 FY2024 | Nov 7, 2024 | -$0.48 | -$0.44 | +8.3% | — | $0.00B | — |
Q3 FY2026
Aug 4, 2026
EPS Actual
—
EPS Est.
-$0.47
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Miss
EPS Actual
-$0.54
EPS Est.
-$0.51
EPS Surpr.
-5.9%
Revenue
$0.00B
Q1 FY2026
Mar 9, 2026Beat
EPS Actual
-$0.34
EPS Est.
-$0.60
EPS Surpr.
+43.3%
Revenue
$0.00B
Q4 FY2025
Nov 6, 2025Miss
EPS Actual
-$0.59
EPS Est.
-$0.56
EPS Surpr.
-5.4%
Revenue
$0.00B
Q3 FY2025
Aug 5, 2025
EPS Actual
-$0.41
EPS Est.
-$0.41
EPS Surpr.
+0.0%
Revenue
$0.00B
Q2 FY2025
May 8, 2025
EPS Actual
-$0.35
EPS Est.
-$0.35
EPS Surpr.
+0.0%
Revenue
$0.00B
Q1 FY2025
Mar 13, 2025Beat
EPS Actual
$0.33
EPS Est.
-$0.40
EPS Surpr.
+182.5%
Revenue
$0.00B
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
-$0.44
EPS Est.
-$0.48
EPS Surpr.
+8.3%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.51 | $-0.51 | $-0.51 | 1 |
| Q3 FY2026 | $-0.45 | $-0.45 | $-0.45 | 1 |
| Q2 FY2026 | $-0.43 | $-0.43 | $-0.43 | 1 |
| Q1 FY2026 | $-0.48 | $-0.48 | $-0.48 | 1 |
| Q4 FY2025 | $-0.61 | $-0.61 | $-0.61 | 1 |
| Q3 FY2025 | $-0.54 | $-0.54 | $-0.54 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 7, 2026 | -5.9% | $2.43 | $2.39 | -1.65% |
| ▲ Q1 FY2026 | Mar 9, 2026 | +43.3% | $8.13 | $7.88 | -3.08% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -5.4% | $2.56 | $2.64 | +3.13% |
| ▲ Q3 FY2025 | Aug 5, 2025 | +0.0% | $3.13 | $3.08 | -1.60% |
| ▲ Q2 FY2025 | May 8, 2025 | +0.0% | $3.30 | $3.23 | -2.12% |
| ▲ Q1 FY2025 | Mar 13, 2025 | +182.5% | $3.21 | $3.30 | +2.80% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +8.3% | $6.06 | $5.59 | -7.76% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +28.2% | $5.04 | $4.39 | -12.90% |
Q2 FY2026-1.65%
Report Date
May 7, 2026
EPS Beat/Miss
-5.9%
Price Before
$2.43
Price After
$2.39
Q1 FY2026-3.08%
Report Date
Mar 9, 2026
EPS Beat/Miss
+43.3%
Price Before
$8.13
Price After
$7.88
Q4 FY2025+3.13%
Report Date
Nov 6, 2025
EPS Beat/Miss
-5.4%
Price Before
$2.56
Price After
$2.64
Q3 FY2025-1.60%
Report Date
Aug 5, 2025
EPS Beat/Miss
+0.0%
Price Before
$3.13
Price After
$3.08
Q2 FY2025-2.12%
Report Date
May 8, 2025
EPS Beat/Miss
+0.0%
Price Before
$3.30
Price After
$3.23
Q1 FY2025+2.80%
Report Date
Mar 13, 2025
EPS Beat/Miss
+182.5%
Price Before
$3.21
Price After
$3.30
Q4 FY2024-7.76%
Report Date
Nov 7, 2024
EPS Beat/Miss
+8.3%
Price Before
$6.06
Price After
$5.59
Q3 FY2024-12.90%
Report Date
Aug 8, 2024
EPS Beat/Miss
+28.2%
Price Before
$5.04
Price After
$4.39
Avg Beat Reaction-4.11%
Avg Miss Reaction+0.74%
Beat Rate6 / 8 quarters
Largest Move-12.90% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: LPCN ends December
Lipocine Inc. (LPCN) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.54 — missing the analyst consensus of $-0.51 by -5.9%. The next LPCN earnings date is expected around September 1, 2026.
Each quarter, investors track LPCN earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. LPCN revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
LPCN's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
LPCN earnings · 5 questionsLipocine Inc.'s next earnings report is expected around September 1, 2026. LPCN typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; LPCN historically reports after market close (AMC).
LPCN earnings datewhen is LPCN earningsLPCN next earnings datewhen does LPCN report earningsLPCN earnings calendar
▸ Source: FMP · Lipocine Inc. SEC filings · US GAAP · Lipocine Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026